Foscan (temoporfin)
- Region
- 🇪🇺 EU
- Active substance
- temoporfin
- Company
- Biolitec Pharma Ltd
- Status
- Authorised
- Therapeutic area
- Head and Neck Neoplasms; Carcinoma, Squamous Cell
- EU approval
- Wed 24 Oct 2001
- Application
- EMEA/H/C/000318
- ATC
- L01XD05
- Official record
- www.ema.europa.eu
Indication
Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy.
Regulatory milestones
No milestones recorded in the last year.
Follow Foscan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.